Director Bruce C. Cozadd filed a Form 4 with the SEC on November 4, 2026, disclosing a sale of 6,000 ordinary shares of Jazz Pharmaceuticals plc on November 2, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: Bruce C. Cozadd disposed of 6,000 ordinary shares of Jazz Pharmaceuticals plc on November 2, 2026.
  • Sale price: The shares were sold at $215.84 each, according to the filing.
  • Post-transaction ownership: Following the sale, Cozadd directly beneficially owns 339,875 ordinary shares.
  • 10b5-1 plan: The filing states the transaction was made pursuant to a plan adopted by Cozadd on November 26, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  • Automatic execution: According to the filing, "The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."
  • Role: Cozadd is identified in the filing as a Director of Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Cozadd's November 2026 Share Sale Under Scheduled 10b5-1 Plan

Bruce C. Cozadd, a Director of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), reported the disposal of 6,000 ordinary shares on November 2, 2026, at a price of $215.84 per share. The transaction is recorded in Table I of the Form 4 filing under transaction code "S," indicating a sale. Ownership of the disposed shares is listed as direct.

The filing attributes the sale to a Rule 10b5-1 trading plan that Cozadd adopted on November 26, 2025. The filing states the plan was established "in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended," and that the transaction "occurred automatically and does not represent a discretionary transaction by the reporting person." The Form 4 was signed by Paz Dizon as attorney in fact for Bruce C. Cozadd on November 4, 2026.

After the reported sale, Cozadd's direct beneficial ownership of Jazz Pharmaceuticals ordinary shares stands at 339,875, as reported in the filing. No derivative securities transactions were reported in Table II of this filing.

What Was Disclosed

Director Bruce C. Cozadd disclosed the sale of 6,000 Jazz Pharmaceuticals ordinary shares at $215.84 on November 2, 2026, under a pre-scheduled 10b5-1 plan adopted in November 2025, leaving him with direct beneficial ownership of 339,875 shares.